Cyproterone Acetate in Treating Patients With Newly Diagnosed Stage III or Stage IV Prostate Cancer
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Androgens can cause the growth of prostate cancer cells. Hormone therapy, such as
cyproterone acetate may stop the adrenal glands from making androgens. Sometimes the tumor
may not need treatment until it progresses. In this case, observation may be sufficient. It
is not yet known whether giving cyproterone acetate continuously is more effective than
giving cyproterone acetate after tumor progression in treating prostate cancer.
PURPOSE: This randomized phase III trial is studying cyproterone acetate to compare how well
it works when given continuously or after tumor progression in treating patients with newly
diagnosed stage III or stage IV prostate cancer.